Merck & Co., Inc. (MRK) vs Novo Nordisk A/S (NVO)
Merck & Co., Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Merck & Co., Inc. is the larger, with a market value of $365.4B against $129.3B — 2.8× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 119×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 4.64%. Novo Nordisk A/S has the higher net margin (35.5% vs 4.77%) and the higher return on invested capital (28.7% vs 5.08%). Both pay a dividend; Merck & Co., Inc. yields more (2.58% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 18 and Merck & Co., Inc. on 5.
Valuation
Profitability
| Metric | MRK | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 72.97% | 80.73% | 72.77% |
| Operating margin | 10.49% | 43.36% | 18.90% |
| Net margin | 4.77% | 35.47% | 8.27% |
| Free cash flow margin | 24.13% | 14.79% | 17.25% |
| Return on equity | 6.97% | 60.84% | 6.97% |
| Return on assets | 2.57% | 22.00% | 2.76% |
| Return on invested capital | 5.08% | 28.67% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack